Organization (Industry)
Biotronik (Singapore)
ClinicalTrials.gov lists Biotronik (Singapore) as lead sponsor of 73 trials. It has 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 7 in 2026 and about 7 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo Biotronik, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Biotronik (Singapore): 73 lead-sponsored trials and 5 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (56)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Heart Failure | 53 |
| Coronary Disease | 31 |
| Tachycardia | 31 |
| Atrial Fibrillation | 28 |
| Coronary Artery Disease | 28 |
Showing 5 of 56 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 5 |
| 2024 | 6 |
| 2023 | 12 |
| 2022 | 4 |
| 2021 | 11 |
| 2020 | 11 |
| 2019 | 9 |
| 2018 | 9 |
| 2017 | 15 |
Showing 10 of 24 years.
Prediction, not a registry value: median of 30 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 138 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Conventional Treatment | 1 |
| Physician-Directed OAC | 1 |
| Home Monitoring Guided OAC | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 68% hit target (n=53) | 32% on time (n=57) |
Journals published in (67)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Circulation | 38 |
| Journal of the American College of Cardiology | 28 |
| The New England journal of medicine | 27 |
| Pacing and clinical electrophysiology : PACE | 21 |
| EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology | 19 |
Showing 5 of 67 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 468 | 148 | 2025-12-30 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 5 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| BIOTRONIK SE & CO. KG | BERLIN, DE | FDA |
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Assistance Publique – Hôpitaux de Paris | Co sponsors trial with | 1 |
| The University of Texas System | Co sponsors trial with | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | Co sponsors trial with | 1 |
| Saint Antoine University Hospital | Co sponsors trial with | 1 |
| University Hospital, Marseille | Co sponsors trial with | 1 |
Showing 5 of 7 relationships.
Latest dated events (688)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-25 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 688 events.
Biomarker capability evidence (70)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGT | Trial collaborator | Named in trial inclusion criteria |
| BTK | Trial sponsor | Named in trial inclusion criteria |
| BTK | Trial collaborator | Named in trial inclusion criteria |
| BTK | Trial sponsor | Named in trial inclusion criteria |
| MLIP | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 70 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.